Nevola R, Marrone A, Cozzolino D, Cuomo G, Romano C P, Rinaldi L, Aprea C, Padula A, Ranieri R, Gjeloshi K, Ricozzi C, Ruosi C, Imbriani S, Meo L A, Sellitto A, Cinone F, Carusone C, Abitabile M, Nappo F, Signoriello G, Adinolfi L E
Department of Advanced Medical and Surgery Sciences, Internal Medicine COVID Center, Azienda Ospedaliera Universitaria Vanvitelli, University of Campania Luigi Vanvitelli, Naples, Italy.
Eur Rev Med Pharmacol Sci. 2022 Mar;26(5):1777-1785. doi: 10.26355/eurrev_202203_28249.
The first pandemic phase of COVID-19 in Italy was characterized by high in-hospital mortality ranging from 23% to 38%. During the third pandemic phase there has been an improvement in the management and treatment of COVID-19, so mortality and predictors may have changed. A prospective study was planned to identify predictors of mortality during the third pandemic phase.
From 15 December 2020 to 15 May 2021, 208 patients were hospitalized (median age: 64 years; males: 58.6%); 83% had a median of 2 (IQR,1-4) comorbidities; pneumonia was present in 89.8%. Patients were monitored remotely for respiratory function and ECG trace for 24 hours/day. Management and treatment were done following the timing and dosage recommended by international guidelines.
79.2% of patients necessitated O2-therapy. ARDS was present in 46.1% of patients and 45.4% received non-invasive ventilation and 11.1% required ICU treatment. 38% developed arrhythmias which were identified early by telemetry and promptly treated. The in-hospital mortality rate was 10%. At multivariate analysis independent predictors of mortality were: older age (R-R for≥70 years: 5.44), number of comorbidities ≥3 (R-R 2.72), eGFR ≤60 ml/min (RR 2.91), high d-Dimer (R-R for≥1,000 ng/ml:7.53), and low PaO2/FiO2 (R-R for <200: 3.21).
Management and treatment adherence to recommendations, use of telemetry, and no overcrowding appear to reduce mortality. Advanced age, number of comorbidities, severe renal failure, high d-Dimer and low P/F remain predictors of poor outcome. The data help to identify current high-risk COVID-19 patients in whom management has yet to be optimized, who require the greatest therapeutic effort, and subjects in whom vaccination is mandatory.
意大利新冠疫情的第一阶段,院内死亡率高达23%至38%。在第三阶段,新冠病毒的管理和治疗有所改善,因此死亡率及预测因素可能已发生变化。我们开展了一项前瞻性研究,以确定第三阶段疫情期间的死亡预测因素。
2020年12月15日至2021年5月15日,208名患者住院治疗(中位年龄:64岁;男性:58.6%);83%的患者有2种(四分位间距,1 - 4种)合并症;89.8%的患者患有肺炎。每天24小时对患者进行呼吸功能和心电图远程监测。管理和治疗按照国际指南推荐的时间和剂量进行。
79.2%的患者需要吸氧治疗。46.1%的患者出现急性呼吸窘迫综合征(ARDS),45.4%的患者接受无创通气,11.1%的患者需要重症监护治疗。38%的患者出现心律失常,通过遥测早期发现并及时治疗。院内死亡率为10%。多因素分析显示,死亡的独立预测因素为:年龄较大(≥70岁的相对危险度:5.44)、合并症数量≥3种(相对危险度2.72)、估算肾小球滤过率(eGFR)≤60 ml/min(相对危险度2.91)、高D - 二聚体(≥1000 ng/ml的相对危险度:7.53)以及低氧合指数(PaO2/FiO2)(<200的相对危险度:3.21)。
遵循推荐进行管理和治疗、使用遥测技术以及避免过度拥挤似乎可降低死亡率。高龄、合并症数量、严重肾衰竭、高D - 二聚体和低氧合指数仍是预后不良的预测因素。这些数据有助于识别目前管理仍需优化、需要最大治疗力度的高危新冠患者,以及必须接种疫苗的人群。